Trials / Completed
CompletedNCT00082888
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- National Cancer Institute (NCI) · NIH
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tipifarnib may be an effective treatment for non-Hodgkin's lymphoma.
Detailed description
PRIMARY OBJECTIVES: I. To assess tumor response to R115777 (tipifarnib) in patients with relapsed aggressive non-Hodgkin's lymphoma. (Permanently closed to accrual 6/28/06) II. To assess tumor response to R115777 in patients with relapsed indolent non-Hodgkin's lymphoma. (Permanently closed to accrual 9/26/07) III. To assess tumor response to R115777 in patients with uncommon non-Hodgkin's lymphomas. IV. To evaluate toxicity associated with this regimen in patients with relapsed non-Hodgkin's lymphoma. SECONDARY OBJECTIVES: I. To evaluate known and unknown molecular markers that may predict for response to R115777 in lymphoma tissue. OUTLINE: Patients receive tipifarnib orally (PO) twice daily (BID) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 2 years.
Conditions
- Anaplastic Large Cell Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Nodal Marginal Zone Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult T-Cell Leukemia/Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Splenic Marginal Zone Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Laboratory Biomarker Analysis | Correlative studies |
| DRUG | Tipifarnib | Given PO |
Timeline
- Start date
- 2004-03-24
- Primary completion
- 2009-05-20
- Completion
- 2017-07-05
- First posted
- 2004-05-19
- Last updated
- 2020-04-13
- Results posted
- 2011-12-07
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00082888. Inclusion in this directory is not an endorsement.